Department of Radiation Oncology, Shandong University Cancer Center, Jinan, Shandong Province, People's Republic of China.
Department of Breast Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, People's Republic of China.
Virulence. 2022 Dec;13(1):1101-1110. doi: 10.1080/21505594.2022.2092941.
The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, has led to more than 170 million confirmed cases in 223 countries and regions, claiming 3,872,457 lives. Some patients with COVID-19 have mild clinical symptoms despite severe respiratory failure, which greatly increases the difficulty of diagnosis and treatment. It is therefore necessary to identify biological characteristics of SARS-CoV-2, screen novel diagnostic and prognostic biomarkers, as well as to explore potential therapeutic targets for COVID-19. In this comprehensive review, we discuss the current published literature on COVID-19. We find that the comprehensive application of genomics, transcriptomics, proteomics and metabolomics is becoming increasingly important in the treatment of COVID-19. Multi-omics analysis platforms are expected to revolutionize the diagnosis and classification of COVID-19. This review aims to provide a reference for diagnosis, surveillance and clinical decision making related to COVID-19.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的全球大流行,即导致 COVID-19 的病毒,已在 223 个国家和地区导致超过 1.7 亿例确诊病例,夺走 3872457 人的生命。一些 COVID-19 患者尽管存在严重呼吸衰竭,但临床症状较轻,这大大增加了诊断和治疗的难度。因此,有必要确定 SARS-CoV-2 的生物学特征,筛选新型诊断和预后生物标志物,并探索 COVID-19 的潜在治疗靶点。在这篇全面的综述中,我们讨论了目前关于 COVID-19 的已发表文献。我们发现,基因组学、转录组学、蛋白质组学和代谢组学的综合应用在 COVID-19 的治疗中变得越来越重要。多组学分析平台有望彻底改变 COVID-19 的诊断和分类。本综述旨在为 COVID-19 的诊断、监测和临床决策提供参考。